H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix (NASDAQ:OCUL) on Monday, setting a price target of $10, which is approximately 67.50% above the present share price of $5.97.
Chen expects Ocular Therapeutix to post earnings per share (EPS) of -$0.53 for the second quarter of 2020.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Ocular Therapeutix, with an average price target of $9.
The analysts price targets range from a high of $10 to a low of $8.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $2.26 million and a net profit of -$21.4 million. The company's market cap is $318.58 million.
According to TipRanks.com, H.C. Wainwright analyst Yi Chen is a 5-star analyst with an average return of 17.3% and a 44.8% success rate.
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline include Dextenza, OTX-TP, and OTX-TIC . The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.